Sells the INTERCEPT Blood System, designed to reduce pathogens in donated blood components, to blood banks, hospitals and distributors.
10-K for FY2025, filed Mar 2, 2026
Product sales bring money from blood banks, hospitals, universities, government agencies and distributors buying kits, illuminators, fibrinogen complex and other products; invoices generally require payment 30 to 60 days after invoicing, while maintenance pays over its service term. U.S. government contracts reimburse approved project costs as the work is done or pay at milestones.
10-K for FY2025, filed Mar 2, 2026The Company’s main source of revenue is product revenue from sales of the INTERCEPT Blood System for platelets and plasma (“platelet and…View ↗
The Company receives funding under its U.S. government contracts that support research and development of defined projects. The Biomedical…View ↗
The Company invoices its customers based upon the terms in the contracts, which generally require payment 30 to 60 days from the date of…View ↗
10-K for FY2025, filed Mar 2, 2026
FY2025 revenue by product or service ↗$233.8M
10-K for FY2025, filed Mar 2, 2026
$233.8M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product
Mix
10-K for FY2025, filed Mar 2, 2026 |
88%
FY2022: 86%
|
Product, FY2025
$206.1M Sources
|
Mix |
|
Government Contract
Recurring
10-K for FY2025, filed Mar 2, 2026 |
12%
FY2022: 14%
|
Government Contract, FY2025
$27.7M Sources
|
Recurring |
Blood banks and other health-care or government customers buy directly; distributors sell the platelet and plasma systems in some regions.
10-K for FY2025, filed Mar 2, 2026
Not on paper. It lost $15.6M in FY2025, but brought in more cash than it spent: $1.1M of free cash flow.
10-Q for Q3 FY2026, filed Nov 2, 2026
−$550KView ↗
10-Q for Q3 FY2026, filed Nov 2, 2026
Open tableView ↗
8-K, filed Jul 30, 2026
Raising Lower End of 2026 Product Revenue Guidance: Range now $229 to $231 million;Raising 2026 IFC Sales Outlook to $23 to $25 million, up…View ↗
8-K, filed Jul 10, 2026
As previously disclosed, William “Obi” Greenman, former President and Chief Executive Officer and Chairman of the Board of Directors (the…View ↗
Growing. Revenue grew 47% in 4 years, from $159.5M in FY2021 to $233.8M in FY2025, about 10% a year.
Fibrinogen Complex sales focus
Cerus is shifting from selling finished INTERCEPT Fibrinogen Complex doses to hospitals toward selling kits to blood centers; the older report described direct U.S. sales of the product or kits.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Mar 2, 2026Our INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells…View ↗
We expect our commercial efforts in 2026 will be focused on increasing market adoption of INTERCEPT products by enabling blood center…View ↗
Competes with Grifols, Octapharma, MacoPharma International, Kedrion Biopharma, and Terumo
10-K for FY2025, filed Mar 2, 2026In Europe, several companies, including Grifols, Octapharma AG, MacoPharma International and Kedrion Biopharma, have developed in the past…View ↗
Loading...